image credit- freepik
Japan-based Olympus Corporation has announced an additional commitment to its corporate venture capital fund, Olympus Innovation Ventures, LLC (OIV), with the launch of Olympus Innovation Ventures Fund II. Building on the success of the initial fund, Olympus will deploy $150 million to invest in promising MedTech startup companies focused on Gastrointestinal (GI), Urology and Respiratory.
OIV, a wholly owned subsidiary of Olympus Corporation of the Americas, aims to generate a robust pipeline of M&A opportunities, partnerships, and valuable market insights. OIV is stage-agnostic, prioritising early to growth-stage companies globally with therapeutic solutions for targeted medical specialties.
In addition to capital, Olympus will continue to help its portfolio companies succeed by contributing its clinical and technical expertise, access to healthcare professionals and hospitals, and ability to launch and scale innovative solutions in the global market.
OIV focuses on investments in passionate founders who are revolutionising medical solutions. The fund invests in customer-driven solutions in medical devices, diagnostics and digital health. Since its inception in October 2021, OIV has made nine investments in areas such as AI workflow solutions and medical imaging agents for cancer detection.
